Press Releases

09/22/2016

France-Based Laboratoire CERBA Adopts Seraseq™ Aneuploidy Reference Materials for Non-Invasive Prenatal Testing (NIPT)

SeraCare Life Sciences, a manufacturer and leading partner to global in vitro diagnostics manufacturers and clinical laboratories, has signed an agreement with Laboratoire CERBA, a leading European reference laboratory specializing in clinical pathology, to provide custom Seraseq™ Aneuploidy Reference Materials for use with Laboratoire CERBA's non-invasive prenatal testing (NIPT) assay.

08/03/2016

SeraCare Life Sciences Debuts its New Website at AACC

SeraCare Life Sciences, a leading partner to clinical laboratories and global in vitro diagnostics manufacturers, announced at the American Association of Clinical Chemistry (AACC) conference today the launch of its newly redesigned website, www.seracare.com.

06/16/2016

SeraCare and NIST Partner on Development of Circulating Tumor DNA Reference Standards for Diagnostics

SeraCare Life Sciences, a manufacturer and leading partner to global in vitro diagnostics manufacturers, and the U.S. Department of Commerce’s National Institute of Standards and Technology (NIST) have signed of a three-year Cooperative Research And Development Agreement (CRADA) to advance development of circulating tumor DNA (ctDNA) diagnostic assay reference standard materials.

07/28/2015

SeraCare Life Sciences Signs License Agreement with UCSF and Announces Early Access Program for Development of Aneuploidy Reference Materials

SeraCare Life Sciences, a leading partner to global in vitro diagnostics manufacturers, announced today at the American Association of Clinical Chemistry (AACC) meeting that it has signed a licensing agreement with the University of California, San Francisco (UCSF) for the use of Trisomy 21 (T21), Trisomy 18 (T18) and Trisomy 13 (T13) trophoblast cell line material as a component for creating “patient-like” reference materials for Non-Invasive Prenatal Testing (NIPT) of chromosomal abnormalities.